Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
2002-05-31
2010-06-22
Nolan, Patrick J. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
Reexamination Certificate
active
07741453
ABSTRACT:
The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.
REFERENCES:
patent: 4652629 (1987-03-01), Patrick et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5614487 (1997-03-01), Battersby et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 6013263 (2000-01-01), Barney et al.
patent: 6017536 (2000-01-01), Barney et al.
patent: 6063761 (2000-05-01), Jones et al.
patent: 6103236 (2000-08-01), Suzawa et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6150088 (2000-11-01), Chan et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6818611 (2004-11-01), Altman
patent: 7090851 (2006-08-01), Bridon et al.
patent: 7307148 (2007-12-01), Bousquet-Gagnon et al.
patent: 2004/0106589 (2004-06-01), Webb et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 2006/0099571 (2006-05-01), Altman
patent: 2008/0176794 (2008-07-01), Bridon et al.
patent: 2008/0199483 (2008-08-01), Bridon et al.
patent: 2009/0175821 (2009-07-01), Bridon et al.
patent: 0 602 290 (1999-07-01), None
patent: 1 264 840 (2002-12-01), None
patent: WO 95/10302 (1995-04-01), None
patent: 9605389 (1996-02-01), None
patent: WO 96/19495 (1996-06-01), None
patent: 9924076 (1999-05-01), None
patent: WO 99/24074 (1999-05-01), None
patent: WO 99/24075 (1999-05-01), None
patent: WO 99/59615 (1999-05-01), None
patent: WO 99/48536 (1999-10-01), None
patent: 0040616 (2000-07-01), None
patent: 0069900 (2000-11-01), None
patent: 0069911 (2000-11-01), None
patent: 0070665 (2000-11-01), None
patent: WO 00/69902 (2000-11-01), None
patent: 0076550 (2000-12-01), None
patent: 0076551 (2000-12-01), None
patent: 0103723 (2001-01-01), None
patent: 0117568 (2001-03-01), None
patent: 0144286 (2001-06-01), None
patent: 02096935 (2002-12-01), None
patent: 2004028473 (2004-04-01), None
patent: 2004029073 (2004-04-01), None
patent: 2004029201 (2004-04-01), None
patent: 2005007831 (2005-01-01), None
patent: 2005103087 (2005-11-01), None
patent: WO 20058108418 (2005-11-01), None
patent: 2007071068 (2007-06-01), None
US 6,020,459, 02/2000, Barney et al. (withdrawn)
Malashkevich, V., Crystal stucture of the simian immunodeficiency virus (SIV) gp41 core: Conseved helical interactions underlie the broad inhibitory acivity of gp41 peptides, Proc. Natl. Acad. Sci. USA, 95:9134-9, 1998.
Gustchina, E., Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2 and SIV, J. Med. Chem., 48:3036-44, 2005.
Lambert et al., Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion, Proc. Natl. Acad. Sci. USA, 1996, vol. 93, pp. 2186-2191.
Ito et al., CXCR4-Tropic HIV-1 Suppresses Replication of CCR5-Tropic HIV-1 in Human Lymphoid Tissue by Selective Induction of CC-Chemokines, The Journal of Infectious Diseases, 2004, 189:506-514.
Desrosiers, Prospects for an AIDS vaccine, Nature Medicine, 2004, 10(30):221-223.
Ji, h., et al. Buried Polar Interactions and Conformational Stability in the Simian Immunodeficiency Viruys (SIV) gp41 Core, Biochemistry 2000, 39:676-685.
International Search Report for PCT/CA02/00806 (6 pgs).
Annex I of Jun. 6, 2005 to Appellant's letter dated Sep. 15, 2004 in EP 00932570.5.
Annex II of Jun. 6, 2005 to Appellant's letter dated Sep. 15, 2004 in EP 00932570.5.
Annexes I, II and III to Appellant's letter dated May 17, 2004 in EP 00932570.5.
Declaration of Serge Saint-Pierre of Sep. 9, 2004 as cited in Opposition of in EP 00932570.5 by Trimeris, Inc.
Declaration of Dominique Bridon, including exhibits, as cited in Opposition of in EP 00932570.5 by Trimeris, Inc.
Declaration of Grant A. Krafft of Jun. 2005 as cited in Opposition of in EP 00932570.5 by Trimeris, Inc.
Baker et al., (1999) “Structural basis for Paramyxovirus-Mediated Membrane Fusion”, Mole. Cell., 3, 309-319.
Bressanelli et al., (2004) Embo J., 23, 728-738.
Bridon et al., U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, for “Long-Lasting Antiviral Fusion Inhibitor Peptide Conjugates Comprising BSA and DP-178”.
Bullough et al., (1994) “Structure of influenza haemagglutinin at the pH of membrane fusion”, Nature, 371, 37-43.
Caffrey et al., (1998) “Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41” Embo J., 17, 4571-4584.
Chan et al. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
Chan et al. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 95: 15613-15617.
Fass et al., (1995) “Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin”, Curr. Biol. 5, 1377-1383.
Fass et al., (1996) “Retrovirus envelope domain at 1.7 a resolution”, Nat. Struct. Biol. 3, 465-469.
Greenberg et al. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54:333-340.
Groenink et al. (1997) “Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins.”, AIDS Res Hum Retrovir 13: 179-185.
Hamburger et al. (2005) J Biol Chem 280: 12567-12572.
He et al., “Potent HIV Fusion Inhibitors Against Enfuvirtide-Resistant HIV-1 Strains”, PNAS, Oct. 21, 2008. pp. 16332-16337.
Holmes et al. (2000) Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconj Chem 11: 439-444.
Jacobs et al. (2007) J Biol Chem 282: 32406-32413.
Jansen et al. (1993) “Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity”, Mol Pharmacol 44: 1003-1007.
Jetté et al. (2005) “Human growth hormone-releasing factor (hGRF)1-29 albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long-lasting GRF analog,” Endocrinology 146: 3052-3058.
Kliger et al., (2000) “Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation”, J Mol Biol 295: 163-168.
Kratz, et al., “Albumin Conjugates of the Anticancer Drug Chlorambucil: Synthesis, Characterization, and in Vitro Efficacy”, Arch. Pharm. Pharm. Med. Chem., vol. 331, No. 2, pp. 47-53, 1998.
Kratz, et al., “Preparation, Characterization and in Vitro Efficacy of Albumin Conjugates of Doxorubicin”, Biol. Pharm. Bull., vol. 21, No. 1, pp. 56-61, 1998.
Kuiken et al. “HIV Sequence Compendium 2001, Published by Theoretical Biology and Biophysics Group”, Los Alamos National Laboratory, 2002: i-viii; 279-466.
Léger et al. (2003) “Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates,” Bioorg & Med Chem Lett 13: 3571-3575.
Léger et al. (2004) “Kringle 5 peptide-albumin conjugates with anti-migratory activity”, Bioorg & Med. Chem. Lett 14:841-845.
Léger et al. (2004) “Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog,” Bioorg & Med Chem Lett 14: 4395-4398.
Malashkevich, (1999) Biochemistry, 96. 2662-2667.
Manfredi et al., (2006) Curr Med Chem 13: 2369-2384.
Meanwell et al., (2003) Curr Opinion Drug Disc & Develop 6: 451-461.
Modis et al., (2004) Nature, 427, 313-319.
Muñoz-Barroso et al., (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by
Afonina Elena
Bridon Dominique P.
DeMeyer Sandra
Erickson John W.
Krafft Grant A.
Conjuchem Biotechnologies Inc.
Kinsey White Nicole
Lando & Anastasi LLP
Nolan Patrick J.
LandOfFree
Long lasting fusion peptide inhibitors for HIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Long lasting fusion peptide inhibitors for HIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Long lasting fusion peptide inhibitors for HIV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165175